Citopenias post tratamiento de cáncer de mama
Abstract
Breast cancer is the most frequent cancer and the leading cause of cancer-related mortality in women in Uruguay. Recent therapeutic advances had led to important survival increments highlighting the importance of long-term complications in survivors such as second malignancies. Treatment related myelodysplastic syndromes and acute myeloid leukemias are associated with chemotherapy and radiotherapy exposure in the previous 5 to 10 years. The aim of this study was to establish cytopenia prevalence in patients with a history of breast cancer who received radiotherapy and/or chemotherapy up to 10 years ago. We carried out an observational cross sectional, descriptive, cohort study which included women with early-stage breast cancer treated at the Hospital de Clínicas Dr. Manuel Quintela’s Breast Cancer Unit. We studied 45 patients with mean age at diagnosis of 57.7 years. Stage II was the most frequent stage
followed closely by stage I, and the most common histological type was invasive ductal carcinoma, with the majority being ER-positive, PR-positive and HER2-negative. Three patients presented pure anemia (6.7% ), two of them moderate and one mild. None other cytopenia were diagnosed.
This study allowed us to know cytopenia prevalence among early stage breast cancer patients exposed to chemotherapy and or radiotherapy in the last ten years. Our results are in concordance with international reports.
Downloads
References
Cancer today [Internet]. [citado 23 de mayo de 2023]. Disponible en: http://gco.iarc.fr/today/home2. Registro Nacional de Cáncer [Internet]. [citado 23 de mayo de 2023]. Disponible en: https://www.comisioncancer.org.uy/categoria/Registro-Nacional-de-Cancer-143. Fernández JÁ, Ozores PP, López VC, Mosquera AC, López RL. Cáncer de mama. Enfermedades Oncológicas IVMelanoma Cáncer Mama Tumores Ginecológicos. 1 de marzo de 2021;13(27):1506-17.4. Cátedra de Oncología [Internet]. 2023 [citado 23 de mayo de 2023]. Pautas de Oncología Médica para el diagnóstico, tratamiento sistémico y seguimiento. Disponible en: https://www.oncologiamedica.hc.edu.uy/publicaciones/pautas-de-oncologia-medica-para-el-diagnostico-tratamiento-sistemico-y-seguimiento/5. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 1 de enero de 2005;365(9472):1687-717.6. Gray R, Bradley R, Braybrooke J, Liu Z, Peto R, Davies L, et al. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet. 6 de abril de 2019;393(10179):1440-52.7. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. The Lancet. 12 de noviembre de 2011;378(9804):1707-16.8. Dunne C, Burke JP, Morrow M, Kell MR. Effect of Margin Status on Local Recurrence After Breast Conservation and Radiation Therapy for Ductal Carcinoma In Situ. J Clin Oncol. 1 de abril de 2009;27(10):1615-20.9. Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez-MacGregor M. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. Cancer. 2018;124(5):899-906.10. Neutropenia - MeSH - NCBI [Internet]. [citado 15 de noviembre de 2023]. Disponible en: https://www.ncbi.nlm.nih.gov/mesh/6800950311. Anemia - MeSH - NCBI [Internet]. [citado 15 de noviembre de 2023]. Disponible en: https://www.ncbi.nlm.nih.gov/mesh/6800074012. Thrombocytopenia - MeSH - NCBI [Internet]. [citado 15 de noviembre de 2023]. Disponible en: https://www.ncbi.nlm.nih.gov/mesh/6801392113. Godley LA, Larson RA. Therapy-Related Myeloid Leukemia. Acute Myeloid Leuk. 1 de agosto de 2008;35(4):418-29.14. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 19 de mayo de 2016;127(20):2391-405.15. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 1 de enero de 2016;91(1):76-89.16. GESMD [Internet]. [citado 23 de mayo de 2023]. Guías SMD y LMMC. Disponible en: https://www.gesmd.es/actividad-cientifica/guias-smd-y-lmmc-2/17. Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 1 de noviembre de 2020;95(11):1399-420.18. Petrone G, Gaulin C, Derkach A, Kishtagari A, Robson ME, Parameswaran R, et al. Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer. Haematologica. 2023;108(1):161-70.19. Tang Z, Ji Y, Min Y, Zhang X, Xu W, Zhao L, et al. Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database. Front Endocrinol. 17 de marzo de 2022;13:856268.20. CANCER DE MAMA El cáncer de mama es la principal causa de muerte por cáncer en mujeres uruguayas. Datos epidemiológicos de la [Internet]. [citado 13 de noviembre de 2023]. Disponible en: https://scholar.googleusercontent.com/scholar?q=cache:NCIiIWGbWbEJ:scholar.google.com/+tratamiento+de+cancer+de+mama+uruguay&hl=es&as_sdt=0,521. Barrios E, Garau M, Barrios E, Garau M. Cáncer: magnitud del problema en el mundo y en Uruguay, aspectos epidemiológicos. An Fac Med. julio de 2017;4(1):7-161.22. Godani N, Irigoyen V, Mastandrea V, Pérez D, Sciuto P. Tratamiento quirúrgico del cáncer de mama locorregionalmente precoz. 2015 [citado 3 de noviembre de 2023]; Disponible en: https://www.colibri.udelar.edu.uy/jspui/handle/20.500.12008/1883323. Delgado L, Fresco R, Santander G, Aguiar S, Camejo N, Ferrero L, et al. Expresión tumoral de HER-2, receptores de estrógenos y de progesterona y su relación con características clínico-patológicas en pacientes uruguayas con cáncer de mama. Rev Médica Urug. septiembre de 2010;26(3):145-53.24. Camejo N, Amarillo D, Ceriani F, Manfrú L de L, Olea FD, Diaz M, et al. Características clinicopatológicas e índice de masa corporal en mujeres Uruguayas portadoras de cáncer de mama asistidas en el Hospital de Clínicas. Rev Peru Investig En Salud. 30 de septiembre de 2023;7(3):123-30.
Copyright (c) 2024 Florencia de los Santos, Lucía Mendoza, Patricia Pérez, Jorge Francisco Ramos, María Laura Ramos, William Riley, Matilde Boada, Natalia Camejo, Cecilia Castillo, Sofía Grille
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain their copyright and assign to the journal the right of first publication of their work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License. that allows sharing the work as long as the initial publication in this magazine is indicated.
